ClinicalTrials.gg
Status unknownNCT04518696Updated Aug 19, 2020

Suprachoroidal Buckling for the Management of Rhegmatogenous Retinal Detachment

An interventional study of suprachoroidal buckling in Retinal Detachment, sponsored by Fang Wang. Status unknown. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2020-08-19.

Sponsored by Fang Wang · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Aug 2020), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 40 Years
Sex
All
01

Study summary

Study of novel surgical technic-suprachoroidal buckling for therapy of rhegmatogenous retinal detachment.It was excpted to reattached the retina and improve visual function of rhegmatogenous retinal detachment patients.

Read the detailed description

The operation was performed under a surgical microscope with a 25G Chandelier light source and a wide-field observation system to observe the fundus.Location, marking and freezing of the retinal tear on the scleral side .

Subretinal fluid is released from the outside of the sclera as needed. The spherical conjunctiva was opened and the radial full-thickness scleral incision (3mm)was made about 8-13mm away from the retinal tear. A "pocket" is formed by injecting some viscoelastic agent into the posterior edge of the sclera and separating the choroid from the sclera using the Healon packaged cannula (No.27 Rycroft cannula). The Healon 5 syringe was connected with a 450-um special tube (a 23 caliber curved tube with olive tip). The cannula is inserted into the supragromal space under microscopic and was scaned by iOCT . Monitor the location of retinal tear during intubation in real time, and adjust the position of the needle: posterior margin of the tear. Once confirmed in accord with the needle position, sodium hyaluronate injection, injection needles to in front of shift to injection, until the tear was completely surrounded in viscoelastic agent to create the choroid crest, usually need 0.2 mL to 0.5 mL. Exit the duct and close the incision with scleral presutures.

02

Conditions studied

  • Retinal Detachment

Browse trials for

03

In context

Retinal Detachment

200 studies on the registry are indexed under Retinal Detachment; 30 are open to participants now.

This study's planned enrollment of 15 is below the median of 50 across 133 interventional studies indexed under Retinal Detachment.

Browse Retinal Detachment studies →

Lead sponsor

Fang Wang is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (1) Clinical diagnosis of rhegmatogenous retinal detachment; (2)myopia \< 600 degrees; (3) retinal tear were peripheral part, non-proliferative round hole or horseshoe tear, single or multiple tears within one oclock area; (4) PVR grading: Grade A, B, C1, C2; (5) Subretinal fluid was confined around the tear. (6)phakic.

Exclusion criteria

Exclusion Criteria:

  • (1)Cataract, corneal degeneration, genetic diseases; (2)History of internal eye surgery; (3)The other eye was blind; (4)Postoperative follow-up could not be scheduled; (5)Systemic diseases (asthma, heart failure, myocardial infarction, liver failure, kidney failure and other serious diseases); (6)History of aspirin and other anticoagulant drugs; (7)Severe adverse reactions and systemic diseases occurred during follow-up.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    suprachoroidal buckling treatment group

    suprachoroidal buckling for therapy of rhegmatogenous retinal detachment

    Procedure: suprachoroidal buckling

Interventions

  • Proceduresuprachoroidal buckling

    Location, marking and freezing of the retinal tear on the scleral side . Subretinal fluid is released from the outside of the sclera as needed. In the quadrant of the retinal tear, the spherical conjunctiva was opened and the radial full-thickness scleral incision (3mm)was made about 8-13mm away from the retinal tear. After the choroid was exposed, a "pocket" is formed by injecting some viscoelastic agent into the posterior edge of the sclera and separating the choroid from the sclera using the Healon packaged cannula (No.27 Rycroft cannula). The Healon 5 syringe was connected with a 450-um special tube . The cannula is inserted into the supragromal space under microscopic and was scaned by iOCT . Once confirmed in accord with the needle position, sodium hyaluronate injection, usually need 0.2 mL to 0.5 mL, application of anterior chamber puncture or subretinal fluid stable intraocular pressure. Exit the duct and close the incision with scleral presutures.

06

What researchers measure

Primary outcomes

  1. Retina reattachment

    Number of participants who achieved retina reattachment assessed by fundus photography,b-scan ultrasonography and optical coherence tomography.

    Time frame: 3 months post operation

  2. Best Corrected visual Acuity (BCVA)

    Patients' best corrected visual acuity assessed by logarithmic visual acuity charts.

    Time frame: 3 months post operation

  3. Intraocular pressure (IOP)

    Patients' IOP assessed by noncontact tonometer

    Time frame: 3 months post operation

  4. Treatment-related adverse event

    Number of participants with treatment-related adverse events(including suprachoroidal hemorrhage, subretinal hemorrhage, vitreous hemorrhage)

    Time frame: 3 months post operation

Secondary outcomes

  1. Retina reattachment

    Number of participants who achieved retina reattachment assessed by fundus photography,b-scan ultrasonography and optical coherence tomography.

    Time frame: 12 months post operation

  2. Best Corrected visual Acuity (BCVA)

    Patients' best corrected visual acuity assessed by logarithmic visual acuity charts.

    Time frame: 12 months post operation

  3. Intraocular pressure (IOP)

    Patients' IOP assessed by noncontact tonometer

    Time frame: 12 months post operation

  4. Treatment-related adverse event

    Number of participants with treatment-related adverse events(including suprachoroidal hemorrhage, subretinal hemorrhage, vitreous hemorrhage)

    Time frame: 12 months post operation

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Antaki F, Dirani A, Ciongoli MR, Steel DHW, Rezende F. Hemorrhagic complications associated with suprachoroidal buckling. Int J Retina Vitreous. 2020 Apr 16;6:10. doi: 10.1186/s40942-020-00211-6. eCollection 2020. PubMed 32318273 ↗
  • Szurman P, Boden K, Januschowski K. Suprachoroidal Hydrogel Buckling as a Surgical Treatment of Retinal Detachment: Biocompatibility and First Experiences. Retina. 2016 Sep;36(9):1786-90. doi: 10.1097/IAE.0000000000001116. No abstract available. PubMed 27429389 ↗
  • Mikhail M, El-Rayes EN, Kojima K, Ajlan R, Rezende F. Catheter-guided suprachoroidal buckling of rhegmatogenous retinal detachments secondary to peripheral retinal breaks. Graefes Arch Clin Exp Ophthalmol. 2017 Jan;255(1):17-23. doi: 10.1007/s00417-016-3530-8. Epub 2016 Nov 16. PubMed 27853956 ↗
  • El Rayes EN, Mikhail M, El Cheweiky H, Elsawah K, Maia A. SUPRACHOROIDAL BUCKLING FOR THE MANAGEMENT OF RHEGMATOGENOUS RETINAL DETACHMENTS SECONDARY TO PERIPHERAL RETINAL BREAKS. Retina. 2017 Apr;37(4):622-629. doi: 10.1097/IAE.0000000000001214. PubMed 27482642 ↗
  • Boden KT, Januschowski K, Szurman P. [Suprachoroidal Hydrogel Buckle - a New Minimal-Invasive Technique in Treatment of Rhegmatogenous Retinal Detachment]. Klin Monbl Augenheilkd. 2019 Mar;236(3):308-312. doi: 10.1055/s-0043-102947. Epub 2017 Apr 4. German. PubMed 28376555 ↗

Individual participant data

Plan to share: Yes — Summarize the experience and deficiency of clinical research process and operation technology, and complete the preliminary report of clinical research.

Supporting information: Study protocol, Clinical study report

Time frame: 2021.01.31 The follow-up work of the study subjects was completed, and statistical analysis was conducted 2021.10.31 Continue to complete the follow-up of all patients, and make statistical analysis of all the data, and scientifically evaluate the results; Summarize the experience and deficiency of clinical research process and operation technology, and complete the preliminary report of clinical research.

Access criteria: All access

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2020; primary completion for Oct 2020, 1 month later.

Of 55 non-industry interventional studies with no phase under Retinal Detachment, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 49. This study's planned 1 month is below that.

Counting every sponsor, half of 56 studies reached it within 23 months; a quarter within 12 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2020
First posted
Aug 19, 2020
StartEst.
Sep 1, 2020
Primary completionEst.
Oct 31, 2020
CompletionEst.
Dec 31, 2022
Last update
Aug 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04518696
Lead sponsor
Fang Wang
Responsible party
Fang Wang (Chief of department of ophthalmology, Shanghai 10th People's Hospital) — Sponsor-investigator
First posted
Aug 19, 2020
Start date
Sep 1, 2020 (estimated)
Primary completion
Oct 31, 2020 (estimated)
Completion
Dec 31, 2022 (estimated)
Last update
Aug 19, 2020

Study contacts

Fang Wang, MD,phD
Contact
18917683335@163.com
+86-18917683335
Conghui Zhang, MD,phD
Contact
linghui0224@126.com
+86-13671886466
Fang Wang, MD,phD
principal investigator · Department of ophthalmology, Shanghai Tenth People's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion